Travere Therapeutics, Inc.
TVTX
$18.33
$0.703.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -9.95% | 22.15% | 48.25% | -50.89% | -159.82% |
| Total Depreciation and Amortization | 7.58% | 8.64% | 4.71% | 4.13% | -17.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -57.36% | -90.31% | 695.87% | 626.63% | 100.64% |
| Change in Net Operating Assets | 209.84% | 88.91% | -1,961.68% | -141.49% | 245.07% |
| Cash from Operations | 15.97% | -5.63% | 66.18% | -68.87% | -19.18% |
| Capital Expenditure | -- | 100.00% | -- | -- | 6,530.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -274.29% | 60.76% | -72.65% | 696.25% | -113.20% |
| Cash from Investing | -274.11% | 61.22% | -72.73% | 718.87% | -112.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 25,932.22% | -56.31% | -- | -- | 8,845.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,714.29% | 0.00% | 0.00% | 96.08% | -1,604.97% |
| Cash from Financing | 302,332.61% | -94.12% | 248.95% | -523.39% | 119.56% |
| Foreign Exchange rate Adjustments | -312.80% | 515.60% | 62.80% | -123.80% | 783.89% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 437.30% | 137.57% | 26.57% | 82.66% | -217.31% |